Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938082 | 0.83 | TAAR1 (0.47) | TAAR1DAOMAOBMIF | |
| SCHEMBL14938084 | 0.83 | BRD4 (0.39) | TAAR1 | |
| SCHEMBL14938060 | 0.82 | DAO (0.42) | DAOMAOB | |
| SCHEMBL14937887 | 0.82 | PDE2A (0.43) | PDE2ADAOMAOB | |
| SCHEMBL14938133 | 0.81 | NOS1 (0.44) | HMOX1 | |
| SCHEMBL14973101 | 0.79 | PDE2A (0.38) | PDE2ATAAR1DAOMAOBMIF | |
| SCHEMBL14973343 | 0.79 | DAO (0.42) | PDE2ATAAR1DAOMAOBMIF | |
| SCHEMBL14973035 | 0.78 | ASPH (0.42) | PDE2AFLT1KDR | |
| SCHEMBL14938128 | 0.77 | FLT1 (0.43) | PDE2AFLT1KDR | |
| SCHEMBL14938300 | 0.77 | MAOB (0.42) | MAOBHMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642626-B2 | Ethinyl-pyrazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2599775-A1 | ETHINYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | PDE2A 2129/4885TAAR1 150/4885DAO 1443/4885 |
| US-20130123500-A1 | ETHINYL-PYRAZOLE DERIVATIVE | GABRE, GRIN3A, GRIK5 | PDE2A 2431/4885TAAR1 223/4885DAO 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.